Clinical application of allogeneic bone marrow transplantation (BMT) has been limited by toxicity related to cytoreductive conditioning and immune response. In utero hematopoietic stem cell transplantation (IUHSCTx) is a non-ablative approach that achieves mixed chimerism and donor specific tolerance, but has been limited by minimal engraftment. We hypothesized that mixed chimerism achieved by IUHSCTx could be enhanced after birth by non-myeloablative total body irradiation (TBI) followed by same donor BMT. To test this hypothesis, mixed chimerism was created by IUHSCTx in an MHC mismatched strain combination. After birth, chimeric animals received non-myeloablative TBI followed by transplantation of donor congenic BM cells. Our results show that: (1) low level chimerism after IUHSCTx can be enhanced to high level chimerism by this strategy; (2) enhancement of chimerism is TBI dose dependent; (3) the mechanism of TBI enhancement is via a transient competitive advantage for non-irradiated HSC; (4) engraftment observed in the tolerant, fully allogeneic IUHSCTx recipient is equivalent to a congenic recipient; and (5) host reactive donor lymphocytes are deleted with no evidence of GVHD. This study supports the concept of prenatal tolerance induction to facilitate non-myeloablative postnatal strategies for cellular therapy. If clinically applicable, such an approach could dramatically expand the application of IUHSCTx.
Introduction
In utero hematopoietic stem cell transplantation (IUHSCTx) is a non-myeloablative approach to achieve mixed hematopoietic chimerism and donor specific tolerance 1 . Although engraftment of allogeneic or xenogeneic HSC, with resultant long-term, multilineage chimerism has been achieved 2, 3 , engraftment in most circumstances has been minimal, i.e. well below what would be considered therapeutic for most target diseases [4] [5] [6] [7] [8] [9] .
In contrast, high level engraftment has been achieved after IUHSCTx in experimental [10] [11] [12] [13] and clinical circumstances 14, 15 where a competitive or survival advantage exists for donor cells. Thus it appears that competition from a normal host hematopoietic compartment is the primary barrier to successful application of IUHSCTx.
One strategy to circumvent the failure to achieve high level engraftment by
IUHSCTx is to take advantage of the donor specific tolerance associated with mixed chimerism and increase levels of chimerism into the therapeutic range after birth by a nonmyeloablative postnatal regimen. It has been observed in syngeneic mice that low-dose irradiation followed by syngeneic BMT confers a competitive advantage for the nonirradiated cells and results in markedly enhanced levels of chimerism relative to syngeneic BMT alone 16, 17 . We hypothesized that our tolerant chimeras created by IUHSCTx would be immunologically similar to syngeneic animals, and that the competitive advantage conferred on non-irradiated cells would result in a marked enhancement of chimerism with conversion of low level mixed chimerism, to high level chimerism. We tested this strategy in a fully allogeneic murine model of IUHSCTx.
Materials and Methods
Mice. Balb/c (H-2K 
Donor bone marrow harvest and T-cell depletion.
Adult BM was harvested from 6-8 week old donors after sacrifice by flushing the tibias and femurs with Ca ++ /Mg ++ free phosphate buffered saline (PBS, Gibco, Rockville, MD).
Flushed BM was passed through 26 guage needle several times to form a single cell suspension and then filtered through a 70-µm nylon mesh filter and layered over Ficoll (Histopaque 1077, Sigma) . After centrifugation at 600g for 15 minutes, the light density mononuclear cell (LDMC) layer was carefully removed and washed with PBS. CD3 + T cell depletion was performed by incubation of washed cells with FITC-conjugated, anti-CD3 mAb (Pharmingen, San Diego, CA) followed by incubation with anti-FITC microbeads (Miltenyi Biotec, Auburn, CA) and subsequent passage through a Vario MACs magnetic cell sorter (Miltenyi Biotec, Auburn, CA) . Flow cytometry, performed on a FACScan (Becton Dickinson, Mountain View, CA), was used to ensure that CD3 + cells constituted less than 0.5% of the donor bone marrow after depletion. Cells were counted prior to transplant and >95% viability confirmed by trypan blue exclusion.
In utero bone marrow transplantation.
Fetuses of time dated pregnant mice were injected at days 13-14 of gestation as previously described 7, 8 . All fetuses were injected intraperitoneally with a 100-µm (outside diameter) beveled glass micropipette and received 5x10 6 cells in 5 µL of PBS. Control animals of
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Postnatal transplant conditioning.
Peripheral blood of mice transplanted in utero was analyzed by flow cytometry at 4 or 8 weeks of age to identify chimeric mice. Chimeric mice were then subjected to either 0 cGy, 82.5 cGy, 138 cGy or 276 cGy of TBI. PBS injected control mice were subjected to 276 cGy of TBI prior to TCD BMT. Naïve B6 control mice were subjected to 82.5 cGy or 276 cGy of irradiation. TBI was delivered as a single dose by a Gammator M-38 cesium 137 irradiator at a rate of 276 cGy/minute unless otherwise stated.
Postnatal bone marrow transplantation.
Six to eight hours after irradiation the mice received donor congenic (B6Pep3b or B6Ly5.2) BM cells. 30x10 6 TCD BM cells, resuspended in 100 µL of PBS, were injected via the lateral tail vein into the chimeric and control mice at either 4 or 8 weeks of life.
Split dose irradiation and duration of irradiation effect studies.
Chimeric mice created by IUHSCTx that were used to analyze the duration of irradiation effect on engraftment as well as the effect of split dose irradiation on engraftment received a postnatal transplant conditioning regimen consisting of either 0 cGy or 82.5 cGy TBI at 4 weeks of life as described above. Six to 8 hours after irradiation the mice received a postnatal BMT by lateral tail vein injection consisting of 30 x 10 6 TCD B6Ly5.2 BM cells.
4 weeks after the initial postnatal transplant, at 8 weeks of age, the mice received a second transplant. Mice used to study the duration of irradiation effect on engraftment received the second transplant without any pre-transplant conditioning. Mice used to study the effects of split dose irradiation on engraftment received 82.5 cGy TBI 6-8 hours prior to the second transplant. In all mice, the second postnatal transplant consisted of 30 x 10 6 TCD B6GFP BM cells, resuspended in 100µl of PBS.
Competitive repopulation assay.
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Blood Sampling and Flow CytometricAnalysis.
Chimerism levels were assessed in recipients of in utero transplantation at 4 or 8 weeks of life prior to receipt of postnatal transplants. Chimerism levels were again assessed every week in all mice after receipt of a postnatal transplant for the first 8 weeks, followed by 
Assessment of hematological parameters.
Naïve Balb/c mice were irradiated with 0 cGy, 82.5 cGy or 276 cGy of irradiation at a rate of 276 cGy/minute from a cesium 137 irradiator. 100 µL of peripheral blood was collected in heparinized tubes by retro-orbital vein puncture prior to irradiation and at days 2, 4, 8, 16 and 23 post irradiation. Hematological parameters (white blood count (WBC), hemoglobin (Hgb) and platelets) were assessed with a HemaVet CBC machine (Mascot, CDC Technologies, Oxford, CT). 
Statistical methods.
Data is graphically represented as the mean of the respective group ± 1 standard deviation.
Statistical comparisons between groups were performed with the Student's t-Test for two samples assuming unequal variances. A two tailed p value of < 0.05 was considered significant.
Results
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Low dose TBI does not depress hematologic parameters in normal mice. chimerism that were stable for up to 32 weeks after transplant ( Figure 2B ). The levels of chimerism present in this study were consistently associated with donor specific tolerance as assessed by MLR ( Figure 2C ). Skin grafts were not performed on the experimental Chimeric mice after IUHSCTx received one of four doses of TBI followed by a postnatal TCD BM transplant with cells congenic (B6Pep3b) to the allogeneic prenatal donor at 4 (A) or 8 (B) weeks of age. Control mice were 4 week old naïve Balb/c males that received 276 cGy of TBI followed by tail vein infusion of 30 X 10 6 TCD B6 BM cells. At all time points there is no difference between chimerism levels in mice boosted at 8 and 4 weeks of age (p>0.05) with the exception of the two marked points (*). Levels of chimerism were statistically different between each irradiation dose with the exception of the # marked point where p>0.05. Phenotypic analysis of peripheral blood chimerism was performed at 8 and 24
weeks after TBI and TCD BMT to assess multilineage engraftment. Donor cell chimerism was multilineage in all irradiation groups after TBI and TCD BMT with no significant The ability to determine which donor population is responsible for the increase in engraftment at the different irradiation doses lends insight into the mechanism by which TBI followed by TCD BMT augments engraftment. Comparison of Figure 5A , which represents chimerism levels in mice that received no pre-transplant TBI to figures 5B, 5C and 5D, which represent mice that received pre-transplant TBI, demonstrates that the postnatal non-irradiated donor cell population is responsible for the entire increase in donor cell chimerism. This is in contrast to mice that did not receive pre-transplant TBI, in which the time required for the postnatal transplant population to represent the majority of the total donor chimerism is longer and more gradual ( Figure 5 ) with no increase in total levels of donor chimerism (Figure 3 . We sought to evaluate the effect on enhancement of donor chimerism of split dose irradiation, using our lowest TBI dose, with TCD BMT following each dose of TBI. A system of three congenic donors, (B6, B6Ly5.2 and 6 B6GFP TCD BM cells 6-8 hours after each TBI dose respectively (Split dose TBI/BMT x 2). Chimerism levels were compared to levels in mice which received a single irradiation dose of 82.5 cGy TBI at 4 weeks of age and were transplanted with 30x10 6 B6Ly5.2 TCD BM cells 6-8 hours after TBI at 4 weeks of life and 30x10 6 B6GFP TCD BM cells at 8 weeks of life (TBI/BMT x 2) as well as chimerism levels in mice which received a single dose of 138 cGy or 276cGy TBI at 4 weeks of age and were transplanted with 30x10 6 B6Pep3b TCD BM cells 6-8 hours after irradiation (TBI/BMT). (B) The composition of total donor chimerism of the "Split Dose TBI/BMT x 2" group was assessed by flow cytometry for GFP as well as CD45. 1 and H-2K b .
equvalent to the single dose 276 cGy group despite receiving a significantly lower dose of TBI (165cGy vs 276cGy). One possible explanation for the similar levels of engraftment between these groups despite less TBI is the fact that the recipients of split dose TBI and TCD BMT receive twice as many HSC as the recipients of a single dose of TBI and TCD BMT. Nevertheless, as the clinical objective would be to reduce the total dose of TBI received, and it's potential morbidity, this would represent a viable clinical strategy. Figure   8B demonstrates that in the split dose irradiation group, the majority of chimerism results from the non-irradiated donor cells reconfirming their competitive advantage.
Absence of GVHD or other apparent toxicity in high level chimeras.
To assess for GVHD or other clinical toxicity mice were serially weighed once per . Enhancement of chimerism in a mixed chimera created by IUHSCTx is equivalent to that observed in naïve congenic recipients. Direct comparison of chimerism levels following TBI and BMT in allogeneic chimeras created by IUHSCTx with those following congenic transplantation of a naïve host (A) keeping the recipient strain constant (SJL->B6 and B6Ly5.2 ->B6) or (C) keeping the donor strain constant (B6-> Balb/c and B6->B6Ly5.2). Analysis of multilineage engraftment in these strain combinations was performed at 24 weeks post transplant (B). For all graphs, p>0.05 when comparing congenic to allogeneic strain combination chimerism levels and multilineage engraftment levels unless indicated by *.
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The enhancement of engraftment observed in fully allogeneic mixed chimeras created by IUHSCTx is equivalent to that observed in naïve congenic recipients.
To directly test our hypothesis that a mixed chimera produced by IUHSCTx would demonstrate equivalent engraftment to that observed in a congenic strain combination in which the same low dose TBI and TCD BMT regimen was applied we compared the effect of TBI and TCD BMT in allogeneic chimeras produced by IUHSCTx with postnatal TBI and TCD BMT in naïve congenic mice. The experiment was performed utilizing strain combinations in which the recipient was the same (SJL->B6 vs. B6Ly5.2->B6) or in which the donor was the same (B6->Balb/c vs. B6-> B6Ly5.2). Our results demonstrate that the kinetics and ultimate level of donor cell engraftment are equivalent in allogeneic or congenic systems ( Figures 9A and C) . Chimerism is multilineage at 24 weeks after TCD BMT with similar levels of myeloid and lymphoid engraftment. Although significant differences in levels of donor cells were present within lineages between allogeneic and congenic strain pairs, the levels of lineage engraftment were similar to donor strain controls ( Figure 9B ). This data argues against any MHC or MHC linked barrier to engraftment in a fully allogeneic strain combination once tolerance is achieved by IUHSCT.
Postnatal enhancement of engraftment after IUHSCTx by this strategy does not appear to be strain specific.
We have noted considerable strain dependence for the level of engraftment after IUHSCTx in the murine model. For instance, in the two allogeneic strain combinations used in this study, IUHSCTx alone of 5 x 10 6 TCD BM cells results in levels of engraftment of 3-10% in B6->Balb/c chimeras and only around 2% in SJL/J->B6 chimeras.
To determine whether the ability to enhance engraftment using TBI and TCD BMT was also strain dependent we compared this regimen in the two fully allogeneic strain combinations ( Figure 10 ). In this experiment we achieved equivalent postnatal enhancement 
Discussion
Cytoreductive conditioning utilizing lethal irradiation or cytotoxic drugs has traditionally been utilized to overcome allogeneic barriers in BMT. The conditioning regimen has been considered necessary for two primary reasons; to suppress the host immune system; and to create "space" in the host BM for engraftment of transplanted HSC. Recently, the requirement for myeloablation to engraft donor HSC has been challenged by a number of observations. Observations in the non-myeloablated, syngeneic mouse model have supported the ability to engraft donor cells with no conditioning in the absence of an immune barrier 16, [22] [23] [24] . In addition, in tolerant systems or immunosuppressed systems, minimally or non-myeloablative regimens have successfully achieved engraftment 25, 26 . However, the primary obstacle to the application of non-myeloablative approaches in clinical BMT remains the immune system. The requirement for immune For personal use only. on November 16, 2017. by guest www.bloodjournal.org From suppression is fundamental to the success of clinical non-myeloablative approaches and application across HLA barriers has been limited by graft failure, toxicity and GVHD [27] [28] [29] .
In contrast, IUHSCTx can achieve donor specific tolerance without the need for immunosuppression. Studies in transgenic mice have documented the role of the fetal thymus in self-recognition and the determination of repertoire of response to foreign antigen [30] [31] [32] . The end result of this process is deletion of T-cell clones with high affinity for self-antigen, and preservation of a T-cell repertoire against foreign antigen. The introduction of allogeneic cells prior to completion of this process by IUHSCTx also results in clonal deletion of alloreactive T-cells and we have documented that the presence of clonal deletion in the murine model is dependent upon the level of donor chimerism. In the presence of "microchimerism" where donor cells are only detectable by PCR, tolerance is inconsistent and when present is associated with only partial clonal deletion and anergy of residual donor reactive host cells 7, 8 . This form of tolerance is relatively weak, and can be "broken" by postnatal administration of antigen. In the presence of higher levels of chimerism (> 1-2%) deletional tolerance is consistently achieved 33, 34 and can be enhanced by postnatal administration of additional donor BM.
In our previous efforts to enhance engraftment, multiple transplants of high doses of donor cells in the first week of life resulted in small but sustained increases in engraftment, analogous to observations in the non-myeloablated syngeneic model 35 . However, the ultimate levels of mixed chimerism remained too low to be therapeutic for most potential target diseases. The primary difference in this study relative to our previous efforts is the addition of low dose TBI prior to TCD BMT. The addition of low-dose TBI as a non-toxic conditioning regimen was suggested to us by the study of Stewart et.al. 19 in which the syngeneic non-myeloablation model was modified by exposure of the host to low dose TBI We observed no GVHD in this study. Susceptibility to GVHD is in part dependent on the absence of host anti-donor immune response. In previous studies in which we attempted to enhance chimerism in allogeneic chimeras created by IUHSCTx by postnatal transplantation of high doses on non-TCD BM, we have observed GVHD but not loss of chimerism 36 . We were therefore concerned that GVHD might occur after BMT in our without GVHD in two strain combinations. In addition, this has been achieved with a practical number of donor cells and levels of TBI that are associated with no significant myeloablation or other apparent toxicity.
Our success in this study strongly supports the general strategy of prenatal tolerance induction to facilitate postnatal cellular or organ transplantation. The convergence of a number of technologies provides a compelling rationale for further development of prenatal therapies. Advances in maternal screening, molecular diagnosis, the human genome project, and microarray technology make it highly likely that in the near future most human genetic diseases will be diagnosed early in gestation, either from fetal cells or fetal DNA in the maternal circulation. The diagnosis of disorders amenable to cellular therapy early in gestation will provide an optimal opportunity for prenatal stem cell therapy as one option for effected families. In addition, genetic disorders in which organ failure or the need for treatment by non-hematopoietic stem cells could be anticipated would potentially benefit from prenatal tolerance induction. Although, clinical application of IUHSCTx has been limited thus far by minimal engraftment, and the need for a selective advantage for donor cells, the ability to enhance engraftment after birth to near complete donor chimerism, using a non-toxic approach, would dramatically expand the application of IUHSCTx. For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
